Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 26 to 50 of 332

Guidance and quality standards awaiting development
Title	Type
Balloon cryoablation for Barrett's oesophagus	Interventional procedures guidance
Baloxavir marboxil for Influenza [ID6552]	Technology appraisal guidance
Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]	Technology appraisal guidance
Baloxavir marboxil for treating influenza in babies under 1 year [ID6555]	Technology appraisal guidance
Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]	Technology appraisal guidance
Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years [TSID12142]	Technology appraisal guidance
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]	Technology appraisal guidance
Belzutifan with lenvatinib for treating advanced renal cell carcinoma after a PD-1 or PD-L1 inhibitor [ID6476]	Technology appraisal guidance
Belzutifan with pembrolizumab and lenvatinib for untreated advanced clear cell renal cell carcinoma [ID6605]	Technology appraisal guidance
Bemarituzumab with chemotherapy for untreated inoperable HER2-negative advanced gastric or gastro-oesophageal junction cancer [ID6481]	Technology appraisal guidance
Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer [TSID11769]	Technology appraisal guidance
Benralizumab for treating hypereosinophilic syndrome in people 12 years and over [ID6322]	Technology appraisal guidance
Benralizumab to reduce exacerbations in moderate to very severe chronic obstructive pulmonary disease [ID1394]	Technology appraisal guidance
Bentracimab for reversing the antiplatelet activity of ticagrelor [TSID10550][ID6344]	Technology appraisal guidance
Bepirovirsen for treating chronic hepatitis B [ID6608]	Technology appraisal guidance
Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years [ID6537]	Technology appraisal guidance
Bevacizumab (Avastin and biosimilars) with fluoropyrimidine-based chemotherapy for untreated metastatic colorectal cancer [ID6465]	Technology appraisal guidance
BI 1015550 for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis [ID6446]	Technology appraisal guidance
Bifikafusp alfa–onfekafusp alfa for neoadjuvant treatment of 3B or 3C resectable melanoma [ID6384]	Technology appraisal guidance
Bimekizumab for treating ankylosing spondylitis [TSID10334]	Technology appraisal guidance
Blarcamesine for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [TSID12157]	Technology appraisal guidance
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease [TSID11991]	Technology appraisal guidance
Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa [TSID10592]	Technology appraisal guidance
Botulinum toxin type A for preventing episodic migraine [ID6450]	Technology appraisal guidance
Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma [ID6437]	Technology appraisal guidance

Results per page

10
25
50
All